BridgeBio Pharma (BridgeBio Pharma) Operating Margin %

: -10,123.90% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. BridgeBio Pharma's Operating Income for the three months ended in Dec. 2023 was $-176.66 Mil. BridgeBio Pharma's Revenue for the three months ended in Dec. 2023 was $1.75 Mil. Therefore, BridgeBio Pharma's Operating Margin % for the quarter that ended in Dec. 2023 was -10,123.90%.

The historical rank and industry rank for BridgeBio Pharma's Operating Margin % or its related term are showing as below:

BBIO' s Operating Margin % Range Over the Past 10 Years
Min: -6443.56 Med: -827.12 Max: -603.28
Current: -6443.56

BBIO's Operating Margin % is ranked worse than
88.78% of 1025 companies
in the Biotechnology industry
Industry Median: -179.29 vs BBIO: -6443.56

BridgeBio Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

BridgeBio Pharma's Operating Income for the three months ended in Dec. 2023 was $-176.66 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-599.44 Mil.

BridgeBio Pharma Operating Margin % Historical Data

The historical data trend for BridgeBio Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Margin %

-656.41

-5,751.99

-827.12

-603.28

-6,443.56

BridgeBio Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Margin %																-6,499.52	-6,724.75	-8,687.87	-3,847.96	-10,123.90

Competitive Comparison

For the Biotechnology subindustry, BridgeBio Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Operating Margin % falls into.

BridgeBio Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

BridgeBio Pharma's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %	=	Operating Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-599.444	/	9.303
	=	-6,443.56 %

BridgeBio Pharma's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %	=	Operating Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-176.662	/	1.745
	=	-10,123.90 %

BridgeBio Pharma (NAS:BBIO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.

Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

BridgeBio Pharma Operating Margin % Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma (BridgeBio Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » Operating Margin %

Comparable Companies

Traded in Other Exchanges

2CL:Germany

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

Executives

Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Frank Mccormick	officer: Chairman of Oncology	C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Neil Kumar	director, officer: See Remarks	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Brian C Stephenson	officer: See Remarks	3160 PORTER DR, STE 250, PALO ALTO CA 94304
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille	director	175 WATER STREET, NEW YORK NY 10038
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Ronald J Daniels	director	C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee	director	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Andrea Ellis	director	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
Richard H Scheller	director, officer: See Remarks	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990